Collectively, these therapeutic strategies, including oncolytic vectors, neutralizing antibodies, Fc-engineered fusion proteins, and small-molecule inhibitors, highlight the centrality of SIRPα-mediated immune suppression in cancer and offer versatile avenues for therapeutic intervention. The gene discussed is SIRPA; the disease is cancer.